• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many people gripped by depression, traditional therapies and medication isn't effective. The individual approach to treatment could be the solution.

Cue is an intervention platform that transforms sensor data collected from smartphones into personalised micro-interventions to improve mental health. We analyzed the most effective-fit personal ML models for each subject using Shapley values to identify their predictors of feature and reveal distinct features that deterministically change mood as time passes.

Predictors of Mood

Depression is a leading cause of mental illness in the world.1 Yet the majority of people affected receive treatment. To improve the outcomes, doctors must be able identify and treat patients who are most likely to respond to specific treatments.

Personalized depression treatment can help. Using sensors for mobile phones, an artificial intelligence voice assistant and other digital tools researchers at the University of Illinois Chicago (UIC) are developing new methods to determine which patients will benefit from the treatments they receive. Two grants worth more than $10 million will be used to identify biological and behavioral predictors of response.

The majority of research done to date has focused on sociodemographic and clinical characteristics. These include demographic variables like age, sex and education, clinical characteristics including symptoms severity and comorbidities and biological markers like neuroimaging and genetic variation.

Few studies have used longitudinal data to determine mood among individuals. A few studies also consider the fact that mood can differ significantly between individuals. It is therefore important to devise methods that allow for the determination and quantification of the individual differences in mood predictors and treatment effects, for instance.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team can then develop algorithms to detect patterns of behavior and emotions that are unique to each individual.

In addition to these methods, the team developed a machine-learning algorithm to model the dynamic predictors of each person's depressed mood. The algorithm combines the individual differences to create an individual "digital genotype" for each participant.

This digital phenotype has been linked to CAT DI scores which is a psychometrically validated symptom severity scale. However the correlation was tinny (Pearson's r = 0.08, the BH-adjusted p-value was 3.55 x 10-03) and varied widely among individuals.

Predictors of symptoms

Depression is a leading reason for disability across the world, but it is often untreated and misdiagnosed. In addition the absence of effective treatments and stigmatization associated with depression disorders hinder many people from seeking help.

To help with personalized treatment, it is essential to identify the factors that predict symptoms. However, current prediction methods depend on the clinical interview which has poor reliability and only detects a small number of features associated with residential depression treatment uk.2

Machine learning can be used to integrate continuous digital behavioral phenotypes that are captured by sensors on smartphones and a validated online tracker of mental health (the Computerized Adaptive Testing Depression Inventory CAT-DI) together with other predictors of symptom severity could improve the accuracy of diagnosis and treatment efficacy for depression. Digital phenotypes permit continuous, high-resolution measurements and capture a wide variety of distinctive behaviors and activity patterns that are difficult to capture using interviews.

The study included University of California Los Angeles students who had mild to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and Depression program29 that was developed as part of the UCLA Depression Grand Challenge. Participants were referred to online support or clinical care according to the degree of their depression. Patients who scored high on the CAT-DI of 35 or 65 were assigned online support via an online peer coach, whereas those who scored 75 patients were referred to psychotherapy in person.

At baseline, participants provided the answers to a series of questions concerning their personal demographics and psychosocial features. The questions included age, sex, and education and financial status, marital status and whether they were divorced or not, current suicidal thoughts, intentions or attempts, as well as the frequency with which they consumed alcohol. Participants also rated their level of private depression treatment (just click the following document) symptom severity on a scale of 0-100 using the CAT-DI. The CAT-DI assessment was performed every two weeks for participants who received online support, and weekly for those who received in-person care.

Predictors of homeopathic treatment for depression Reaction

Research is focusing on personalized treatment for depression. Many studies are focused on identifying predictors, which will help clinicians identify the most effective drugs to treat each patient. Pharmacogenetics in particular is a method of identifying genetic variations that affect the way that our bodies process drugs. This allows doctors to select drugs that are likely to work best for each patient, minimizing the time and effort involved in trial-and-error procedures and avoid any adverse effects that could otherwise hinder advancement.

Another promising approach is to build prediction models combining clinical depression treatments data and neural imaging data. These models can be used to determine which variables are most predictive of a specific outcome, like whether a drug will improve mood or symptoms. These models can also be used to predict the response of a patient to a treatment they are currently receiving and help doctors maximize the effectiveness of current treatment.

A new generation uses machine learning techniques like the supervised and classification algorithms, regularized logistic regression and tree-based methods to integrate the effects of multiple variables and improve predictive accuracy. These models have been demonstrated to be useful in predicting treatment outcomes like the response to antidepressants. These models are getting more popular in psychiatry and it is expected that they will become the standard for future clinical practice.

In addition to the ML-based prediction models research into the mechanisms behind depression continues. Recent findings suggest that depression is linked to dysfunctions in specific neural networks. This suggests that individual depression treatment will be built around targeted treatments that target these circuits to restore normal function.

Internet-based-based therapies can be an option to accomplish this. They can provide an individualized and tailored experience for patients. A study showed that a web-based program improved symptoms and improved quality of life for MDD patients. A controlled study that was randomized to a personalized treatment for depression found that a significant number of patients experienced sustained improvement and had fewer adverse effects.

Predictors of Side Effects

In the treatment of depression, one of the most difficult aspects is predicting and identifying the antidepressant that will cause no or minimal negative side negative effects. Many patients take a trial-and-error method, involving several medications being prescribed before settling on one that is effective and tolerable. Pharmacogenetics offers a fascinating new way to take an effective and precise approach to choosing antidepressant medications.

Several predictors may be used to determine which antidepressant to prescribe, such as gene variants, phenotypes of patients (e.g. gender, sex or ethnicity) and co-morbidities. However, identifying the most reliable and valid predictors for a particular non pharmacological treatment for depression is likely to require controlled, randomized trials with considerably larger samples than those typically enrolled in clinical trials. This is because it could be more difficult to detect interactions or moderators in trials that contain only one episode per person rather than multiple episodes over a period of time.

Additionally the prediction of a patient's response will likely require information on comorbidities, symptom profiles and the patient's personal perception of the effectiveness and tolerability. At present, only a handful of easily measurable sociodemographic variables as well as clinical variables are reliable in predicting the response to MDD. These include age, gender and race/ethnicity, SES, BMI and the presence of alexithymia.

The application of pharmacogenetics to depression treatment is still in its beginning stages and there are many obstacles to overcome. It is crucial to be able to comprehend and understand the definition of the genetic mechanisms that underlie depression, as well as an accurate definition of a reliable indicator of the response to treatment. In addition, ethical concerns such as privacy and the responsible use of personal genetic information should be considered with care. Pharmacogenetics can be able to, over the long term, reduce stigma surrounding treatments for mental illness and improve the quality of treatment. But, like any approach to psychiatry careful consideration and implementation is required. At present, it's best to offer patients a variety of medications for depression that are effective and urge them to speak openly with their physicians.